Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice Abstract #1417

Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.
Aim(s): Evaluation of EVE tolerability according to prior therapies for pts with advanced NETs in the community setting.
Materials and methods: Retrospective analysis on pts with advanced G1-G2 NETs treated with EVE in 10 Spanish University hospitals between June-2009 and June-2015.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1213 Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1413 Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies
Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#568 Efficacy of Everolimus and Tolerability with Long-Term Use
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld